Organon reaches settlement in case involving Mircette

Arnhem, the Netherlands, December 2, 2005 – Akzo Nobel’s human healthcare business, Organon, has reached a settlement in a court case concerning a generic version of Organon’s Mircette® oral contraceptive.

The agreement terminates a patent litigation involving Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. Barr has agreed to pay Organon USD 139 million for the settlement of the patent litigation and the acquisition of all rights relating to Mircette, including the U.S. marketing approval. ---